Seattle-based cancer drug developer Cell Therapeutics (NASDAQ: [[ticker:CTIC]]) announced in a press release today that it has raised $30 million by selling preferred stock and warrants to purchase shares of its common stock to a single institutional investor. The money will be used as operating capital by the company. The offer is expected to close on Monday.